Prognostic Factors in Patients with Stage II/III Breast Cancer Treated with Adjuvant Extension of Neoadjuvant Chemotherapy: A Retrospective Cohort Study with Ten-Years of Follow-Up Data.

J Breast Cancer · 2011 · PMC3148511 · PMID 21847393

Europe PMC DOI

hedged sentence

0.0530

closest p · 1.1× alpha

0.0530

boldest claim

The sentences

a strong trendp =0.053so close (0.05 < p ≤ 0.1)

Five-year DFS also demonstrated a strong trend in favor of the neoadjuvant group (HR, 0.81, p =0.053) [ 13 ].

also in 5,725 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.